U.K. families face lengthy court battle in Avandia case; Sanofi anticipates Lemtrada ruling in second half of year;

@FiercePharma: Vertex numbers suffer from Incivek sales swoon. Hep C drug down 51%. Whoa. Fewer new pts. More | Follow @FiercePharma

 @AlisonBFierce: Life established an international flu network to up the speed and efficiency of flu monitoring and vaccine development. Release | Follow @AlisonBFierce

@EricPFierce: The world's largest OTC plant gets under way. More | Follow @EricPFierce

> U.K. families seeking compensation for damage caused by GlaxoSmithKline's ($GSK) now-withdrawn diabetes drug Avandia face a lengthy court battle. Item

> Ipsen's fourth-quarter sales fell 0.3% to 294.9 million euros ($397.5 million) due to a drop in demand for drugs sold via primary-care facilities. Story

> Sanofi ($SNY) anticipates an FDA ruling on its application for the new multiple sclerosis treatment Lemtrada by the second half of 2013. News

> PDL BioPharma ($PDLI) will pay regular, quarterly dividends to its stockholders at 15 cents per share of common stock. Release

> Boehringer Ingelheim started testing a version of Roche's ($RHHBY) Rituxan for non-Hodgkin's lymphoma, broadening possible uses for its copy of the drug. Article

Medical Device News

 @FierceMedDev: In case you missed it... The top medical device venture capital investments of 2012. Special Report | Follow @FierceMedDev

 @MarkHFierce: This just in: Boston Scientific's CEO says the medical device tax, in part, is forcing up to 1,000 more layoffs. Article | Follow @MarkHFierce

 @DamianFierce: Medtronic ups the ante in China, buying a $66.2M stake in a Shenzhen cardiovascular biz. More | Follow @DamianFierce

> St. Jude study targets broader renal denervation use. Report

> Autism blood Dx might focus on fat metabolism marker. News

> Roche Diagnostics leaps 4% in 2012, snags 20% market share. Story

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: Cypher Genomics chief speaks out from DNA data-crunching crowd. News | Follow @FierceBiotech

@JohnCFierce: Are we in for a string of winning biotech IPOs? Been a long time: First biotech IPO of '13 jumps in encouraging debut. More | Follow @JohnCFierce

@RyanMFierce: Is Pfizer stronger long-term without generics or just temporarily satisfying Wall Street? Report | Follow @RyanMFierce

> FDA staffers frown over Pharmaxis data for inhaled CF treatment. Article

> Boehringer gets FDA panel's thumbs up on 'modest' new COPD treatment. News

> FDA hands Sanofi, Isis an approval for HoFH drug Kynamro. Story

Drug Delivery News

> Sanofi launches 'talking' emergency epinephrine injector. Report

> Sustained-release contact lenses deliver eye drugs post-surgery. Article

> DNA vaccine tattoo triggers HIV immune response. News

> MIT researchers deliver to cells with a squeeze. Story

> Tunable jelly takes ups and downs out of peptide delivery. Item

And Finally... Studies have shown that women respond differently than men to many drugs, including the sleeping pill Intermezzo. Report (sub. req.)

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.